Dr. Nadia Ghazali (@nnadiagee) 's Twitter Profile
Dr. Nadia Ghazali

@nnadiagee

Clinical Fellow Medical Oncology.
Proud full time working mum.
Supporting women in medicine.

ID: 43644949

calendar_today31-05-2009 05:01:49

15,15K Tweet

690 Followers

644 Following

ACS Journal Cancer (@journalcancer) 's Twitter Profile Photo

New supplement! 📗 Major advances in the systemic treatment of #NSCLC have been made over the past 20 years. CANCER is pleased to deliver 8 comprehensive reviews on targeted therapies for NSCLC written by leading global experts. acsjournals.onlinelibrary.wiley.com/toc/10970142/2… OncoAlert

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

Evolution of HER2 testing over 40 yrs. IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging. We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25. Stay tuned. nature.com/articles/s4157…

Evolution of HER2 testing over 40 yrs.

IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging.

We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25.

Stay tuned.

nature.com/articles/s4157…
International Society of Liquid Biopsy (@isliquidbiopsy) 's Twitter Profile Photo

🚨 New Perspective on ctDNA in NSCLC: Understanding Acquired Resistance 🧬🩸 📖 NatureRevClinOncol , 2025 🔬 This expert review outlines how circulating tumor DNA (ctDNA) is reshaping the detection of acquired resistance to targeted therapies in metastatic NSCLC. 🔍 Key

🚨 New Perspective on ctDNA in NSCLC: Understanding Acquired Resistance 🧬🩸
📖 <a href="/NatRevClinOncol/">NatureRevClinOncol</a> , 2025

🔬 This expert review outlines how circulating tumor DNA (ctDNA) is reshaping the detection of acquired resistance to targeted therapies in metastatic NSCLC.

🔍 Key
Anthony Albanese (@albomp) 's Twitter Profile Photo

Vegemite is back on the menu in Canada. Thanks to Prime Minister @markjcarney for working with Australia to make it happen. 🇦🇺🇨🇦

International Society of Liquid Biopsy (@isliquidbiopsy) 's Twitter Profile Photo

🎉 Mark Your Calendars! The 7th Annual ISLB Congress is coming to Orlando, Florida 🇺🇸 | Nov 1–3, 2025 🧬🩸 Join scientists, clinicians, and innovators from around the world to shape the future of liquid biopsy. Expect: ✅ Groundbreaking science ✅ Networking with global leaders

🎉 Mark Your Calendars!
The 7th Annual ISLB Congress is coming to Orlando, Florida 🇺🇸 | Nov 1–3, 2025 🧬🩸

Join scientists, clinicians, and innovators from around the world to shape the future of liquid biopsy. Expect:
✅ Groundbreaking science
✅ Networking with global leaders
ACS Journal Cancer (@journalcancer) 's Twitter Profile Photo

📗 From the Targeted Therapies in NSCLC supplement | A review discussing ALK-positive lung cancer, including treatment efficacy, safety profiles, mechanisms of resistance, and promising new treatments in the field. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert Dr. Nadia Ghazali IASLC

📗 From the Targeted Therapies in NSCLC supplement | A review discussing ALK-positive lung cancer, including treatment efficacy, safety profiles, mechanisms of resistance, and promising new treatments in the field.

acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

<a href="/OncoAlert/">OncoAlert</a> <a href="/nnadiagee/">Dr. Nadia Ghazali</a> <a href="/IASLC/">IASLC</a>
NASA (@nasa) 's Twitter Profile Photo

Have you started your application to join us this summer as we launch our next crew to the International Space Station? Tell us why you should attend the #Crew11 #NASASocial—Monday, April 28 is your deadline: nasa.gov/social-media/n…

Have you started your application to join us this summer as we launch our next crew to the <a href="/Space_Station/">International Space Station</a>?

Tell us why you should attend the #Crew11 #NASASocial—Monday, April 28 is your deadline: nasa.gov/social-media/n…
Charles Jiang MD, MPH (@charlesjiangmd) 's Twitter Profile Photo

Heading to #ASCO25 for the first time as a trainee? It can be overwhelming but also incredibly rewarding! Here’s some honest advice I wish I’d had as a resident/fellow. 👇 What are YOUR top tips for first-timers? Share & RT!

Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo

🚨 #ASCO25 Update 🚨 🧬 Sacituzumab govitecan (SG) + pembrolizumab vs 💉 Chemo + pembro in 1L PD-L1+ mTNBC 📊 ASCENT-04 / KEYNOTE-D19 results: 🕒 PFS: 11.2 vs 7.8 mo 📉 HR: 0.65 (95% CI: 0.51–0.84), P = .0009 🎯 ORR: 59.7% vs 53.2% ⏳ DOR: 16.5 vs 9.2 mo 📉 Discontinuation due to

🚨 #ASCO25 Update 🚨
🧬 Sacituzumab govitecan (SG) + pembrolizumab
vs
💉 Chemo + pembro in 1L PD-L1+ mTNBC
📊 ASCENT-04 / KEYNOTE-D19 results:
🕒 PFS: 11.2 vs 7.8 mo
📉 HR: 0.65 (95% CI: 0.51–0.84), P = .0009
🎯 ORR: 59.7% vs 53.2%
⏳ DOR: 16.5 vs 9.2 mo
📉 Discontinuation due to
JAMA Oncology (@jamaonc) 's Twitter Profile Photo

Phase 3 oncology RCTs often report positive results based on alternative end points, but actual improvements in overall survival or quality of life are rare, highlighting need to prioritize these outcomes in future research & regulatory processes. #ASCO25 ja.ma/3FCoVHI

Phase 3 oncology RCTs often report positive results based on alternative end points, but actual improvements in overall survival or quality of life are rare, highlighting need to prioritize these outcomes in future research &amp; regulatory processes. #ASCO25 ja.ma/3FCoVHI
Rami Manochakian MD, FASCO Cancer Education (@rmanochakian) 's Twitter Profile Photo

🔥🚨OncoAlert Hot Off The Press Just published NEJM in conjunction with presentation ASCO #ASCO25 Results of #DeLLphi304 phase trial of: #Tarlatamab vs #Chemotherapy in 2nd Tx for advanced #SmallCell #LungCancer ✅#mOS: 13.6 vs 8.3 months (HR: 0.6) ✅More Improvement in

🔥🚨<a href="/OncoAlert/">OncoAlert</a> Hot Off The Press

Just published <a href="/NEJM/">NEJM</a> in conjunction with presentation <a href="/ASCO/">ASCO</a> #ASCO25

Results of #DeLLphi304 phase trial of:
#Tarlatamab vs #Chemotherapy in 2nd Tx for advanced #SmallCell #LungCancer 

✅#mOS: 13.6 vs 8.3 months (HR: 0.6)
✅More Improvement in
Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.
NEJM (@nejm) 's Twitter Profile Photo

Original Article: Structured Exercise after Adjuvant Chemotherapy for Colon Cancer (CHALLENGE phase 3 trial) nej.md/4mh5RPL #ASCO25 | ASCO

Original Article: Structured Exercise after Adjuvant Chemotherapy for Colon Cancer (CHALLENGE phase 3 trial) nej.md/4mh5RPL 

#ASCO25 | <a href="/ASCO/">ASCO</a>
Rami Manochakian MD, FASCO Cancer Education (@rmanochakian) 's Twitter Profile Photo

🔥🚨OncoAlert Hot Off The Press Just published The Lancet In conjunction with presentation ASCO #ASCO25 ✅Results of #IMforte trial of: #Lurbinectedin + #Atezolizumab as 1st line #Maintenance Tx in #Patients with #ExtensiveStage #SmallCell #LungCancer. 👇🏻

🔥🚨<a href="/OncoAlert/">OncoAlert</a> Hot Off The Press

Just published <a href="/TheLancet/">The Lancet</a> 
In conjunction with presentation <a href="/ASCO/">ASCO</a> #ASCO25 

✅Results of #IMforte trial of:

#Lurbinectedin + #Atezolizumab as 1st line #Maintenance Tx in #Patients  
with #ExtensiveStage #SmallCell #LungCancer. 

👇🏻
Dr. Nadia Ghazali (@nnadiagee) 's Twitter Profile Photo

ASCO redeemed itself when you watch orals & the trials presented are positive for OS. Again and again the most important endpoint for any oncology clinical trial is overall survival. Better studies should have been presented in the plenary that actually have an OS benefit

Roberto Borea, MD (@robertoboreamd) 's Twitter Profile Photo

Our review on key advancements in #liquidbiopsy in 2024 is finally out! This work was made possible thanks to the incredible team effort of the International Society of Liquid Biopsy Young Committee. 📰Check it out! ➡️ sciencedirect.com/science/articl…

Our review on key advancements in #liquidbiopsy in 2024 is finally out!

This work was made possible thanks to the incredible team effort of the <a href="/isliquidbiopsy/">International Society of Liquid Biopsy</a>  Young Committee.

📰Check it out! ➡️ sciencedirect.com/science/articl…
International Society of Liquid Biopsy (@isliquidbiopsy) 's Twitter Profile Photo

Great paper from our ISLB Young Committee! A huge effort to keep sharing #LiquidBiopsy knowledge through reviews and editorials after major conferences worldwide. Follow us for more LB updates and insights! 🌍🧬 #ISLB #sciencecommunication